MicroRNA-targeting nanomedicines for the treatment of intervertebral disc degeneration

Adv Drug Deliv Rev. 2024 Feb 22;207:115214. doi: 10.1016/j.addr.2024.115214. Online ahead of print.ABSTRACTLow back pain stands as a pervasive global health concern, afflicting almost 80% of adults at some point in their lives with nearly 40% attributable to intervertebral disc degeneration (IVDD). As only symptomatic relief can be offered to patients there is a dire need for innovative treatments.Given the accumulating evidence that multiple microRNAs (miRs) are dysregulated during IVDD, they could have a huge potential against this debilitating condition. The way miRs can profoundly modulate signaling pathways and influence several cellular processes at once is particularly exciting to tackle this multifaceted disorder. However, miR delivery encounters extracellular and intracellular biological barriers. A promising technology to address this challenge is the vectorization of miRs within nanoparticles, providing both protection and enhancing their uptake within the scarce target cells of the degenerated IVD. This comprehensive review presents the diverse spectrum of miRs' connection with IVDD and demonstrates their therapeutic potential when vectorized in nanomedicines.PMID:38395361 | DOI:10.1016/j.addr.2024.115214
Source: Advanced Drug Delivery Reviews - Category: Drugs & Pharmacology Authors: Source Type: research